Search results for "antineoplastic"

showing 10 items of 2217 documents

Differences in the management and survival of metastatic colorectal cancer in Europe. A population-based study

2020

The management regarding metastatic colorectal cancer throughout Europe is not well known.To draw a European comparison of the management and prognosis of metastatic colorectal cancers.Factors associated with chemotherapy administration were identified through logistic regressions. Net survival was estimated and crude probabilities of death related to cancer and other causes using a flexible cumulative hazard model.Among the 13 227 patients with colorectal cancer diagnosed between 2010 and 2013 in cancer registries from 10 European countries, 3140 were metastatic. 62% of metastatic patients received chemotherapy. Compared to Spain, the related adjusted odds ratios ranged from 0.7 to 4.0 (P0…

MaleOncologymedicine.medical_specialtySurvivalColorectal cancerPopulationAntineoplastic AgentsLogistic regressionMetastasisMetastasis03 medical and health sciences0302 clinical medicineInternal medicineHealth caremedicineHumansRegistriesNeoplasm MetastasisDisease management (health)educationAgedRetrospective StudiesAged 80 and overeducation.field_of_studyHepatologybusiness.industryGastroenterologyDisease ManagementCancerOdds ratioMiddle Agedmedicine.diseaseColorectal cancerEurope030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologyColorectal NeoplasmsbusinessDigestive and Liver Disease
researchProduct

Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study

2017

Background The vast majority of prostate cancer presents clinically localized to the prostate without evidence of metastasis. Currently, there are several modalities available to treat this particular disease. Despite radical prostatectomy demonstrating a modest prostate cancer specific mortality benefit in the PIVOT trial, several novel modalities have emerged to treat localized prostate cancer in patients that are either not eligible for surgery or that prefer an alternative approach. Methods Athymic nude mice were subcutaneously inoculated with prostate cancer cells. The mice were divided into four cohorts, one cohort untreated, two cohorts received docetaxel (10 mg/kg) either subcutaneo…

MaleOncologymedicine.medical_specialtyUrologymedicine.medical_treatmentMice NudeAntineoplastic AgentsDocetaxel02 engineering and technologyMetastasisMice03 medical and health sciencesProstate cancerDrug Delivery Systems0302 clinical medicineProstateIn vivoInternal medicinemedicineAnimalsMinimally Invasive Surgical ProceduresProstatectomybusiness.industryProstatectomyProstatic NeoplasmsProstate-Specific Antigen021001 nanoscience & nanotechnologymedicine.diseaseTumor BurdenSurgeryTreatment Outcomemedicine.anatomical_structureOncologyDocetaxel030220 oncology & carcinogenesisCohortMagnetsImmunohistochemistryTaxoidsDrug Monitoring0210 nano-technologybusinessmedicine.drugThe Prostate
researchProduct

Olfaction in chemotherapy for head and neck malignancies

2015

Abstract Objective Systemic chemotherapy for different malignancies occurs alongside various side effects, including reduced sensory function. To date, little is known about the effect of chemotherapeutic agents on olfaction. The aim of this study was to provide new data about changes in sense of smell during chemotherapy among patients with advanced squamous cell carcinomas of the head and neck region. Methods In a prospective, controlled cohort study of patients undergoing up to three courses of chemotherapy (cis- or carboplatin, 5-fluorouracil and docetaxel), olfaction was evaluated prior to and directly following completing a cycle, as well as 3 weeks later with the beginning of the nex…

MaleOncologymedicine.medical_treatmentDocetaxelSystemic therapyCarboplatinCohort StudiesOlfaction Disorderschemistry.chemical_compound0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsProspective Studies030212 general & internal medicineAged 80 and overSmokingAge FactorsGeneral MedicineMiddle AgedDocetaxelHead and Neck NeoplasmsSensory Thresholds030220 oncology & carcinogenesisCarcinoma Squamous CellFemaleTaxoidsFluorouracilmedicine.drugCohort studyAdultmedicine.medical_specialtyDifferential ThresholdOlfaction03 medical and health sciencesInternal medicinemedicineHumansLaryngeal NeoplasmsAgedCisplatinChemotherapySquamous Cell Carcinoma of Head and Neckbusiness.industryCancerPharyngeal Neoplasmsmedicine.diseaseCarboplatinSurgeryOtorhinolaryngologychemistryControlled Before-After StudiesSurgeryCisplatinbusinessAuris Nasus Larynx
researchProduct

Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas—results of …

2006

Myeloablative radio-chemotherapy with subsequent autologous stem cell transplantation (ASCT) significantly prolongs progression free and probably overall survival in follicular lymphoma (FL) in first remission. The current trial explored prospectively the rate of successful stem cell mobilization in patients with advanced stage FL after initial therapy with either Mitoxantrone, Chlorambucil, Prednisone (MCP) or Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) as part of a prospective randomized comparison of both regimens. ASCT patients received Dexa-BEAM (Dexamethasone, BCNU, Melphalan, Etoposide, Cytarabine) for mobilization of stem cells. Stem cells were collected and a mini…

MaleOncologymedicine.medical_treatmentFollicular lymphomaLymphoma Mantle-CellHematopoietic stem cell transplantationCHOPDexamethasone0302 clinical medicineAutologous stem-cell transplantationGermanyhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesLymphoma FollicularMelphalanEtoposideCytarabineHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell Mobilization3. Good healthSurvival RateTreatment OutcomeOncologyVincristine030220 oncology & carcinogenesisFemalemedicine.drugAdultmedicine.medical_specialtyVincristinePrednisolone03 medical and health sciencesInternal medicinemedicineHumansCyclophosphamideAgedChemotherapyMitoxantronebusiness.industrymedicine.diseaseCarmustineLeukemia Lymphocytic Chronic B-CellSurgeryDoxorubicinPrednisoneChlorambucilMantle cell lymphomaMitoxantronebusiness030215 immunologyAnnals of Oncology
researchProduct

Condensed Versus Standard Schedule of High-Dose Cytarabine Consolidation Therapy with Pegfilgrastim Growth Factor Support in Acute Myeloid Leukemia

2017

Abstract Background: The concept of intensive post-remission chemotherapy in acute myeloid leukemia (AML) is based on the observation that despite achievement of a first complete remission (CR) after intensive induction therapy virtually all patients relapse in the absence of further treatment. Moreover, randomized studies showed that intensive post-remission consolidation chemotherapy was superior to prolonged low-dose maintenance therapy in younger patients. With regard to consolidation therapy, the landmark study conducted by the Cancer and Leukemia Group B established the current standard for patients aged 60 years and younger with high-dose cytarabine (HDAC) 3g/m² bidaily on days days …

MaleOncologymedicine.medical_treatmentHematopoietic stem cell transplantationGastroenterologyBiochemistryPolyethylene Glycols0302 clinical medicineMaintenance therapyAntineoplastic Combined Chemotherapy ProtocolsMedicineCytarabineMyeloid leukemiaHematologyMiddle AgedChemotherapy regimen3. Good healthSurvival RateLeukemia Myeloid AcuteLeukemiaOncology030220 oncology & carcinogenesisOriginal ArticleFemalePegfilgrastimmedicine.drugAdultmedicine.medical_specialtyAdolescentFilgrastimImmunologyPlatelet TransfusionFilgrastimDisease-Free Survival03 medical and health sciencesInternal medicineHumansIdarubicinSurvival rateChemotherapybusiness.industryDaunorubicinConsolidation ChemotherapyCell BiologyLength of Staymedicine.diseaseSurgeryConsolidation ChemotherapyTransplantationPlatelet transfusionCytarabinebusiness030215 immunologyBlood
researchProduct

Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.

2010

BACKGROUND & AIMS: The limited clinical response observed in many patients with colorectal cancer may be related to the presence of chemoresistant colorectal can- cer stem cells (CRC-SCs). Bone morphogenetic protein 4 (BMP4) promotes the differentiation of normal colonic stem cells. We investigated whether BMP4 might be used to induce differentiation of CRC-SCs and for therapeutic purposes. METHODS: CRC-SCs were isolated from 25 tumor samples based on expression of CD133 or using a selection culture medium. BMP4 expression and activity on CRC-SCs were evaluated in vitro; progeny of the stem cells were evaluated by immunofluorescence, immuno- blot, and flow cytometry analyses. The potential …

MaleOrganoplatinum CompoundsCellular differentiationDrug ResistanceApoptosisBone Morphogenetic Protein 4Colon Cancer; Drug Resistance; Neoplasia; Tumor Resistance to Chemotherapy; AC133 Antigen; Adenomatous Polyposis Coli; Aged; Aged 80 and over; Animals; Antigens CD; Antineoplastic Agents; Apoptosis; Bone Morphogenetic Protein 4; Cell Differentiation; Cells Cultured; Colorectal Neoplasms; Female; Fluorouracil; Glycoproteins; Humans; Male; Mice; Microsatellite Instability; Middle Aged; Mutation; Neoplastic Stem Cells; Organoplatinum Compounds; PTEN Phosphohydrolase; Peptides; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Smad4 Protein; GastroenterologyMice80 and overBone morphogenetic protein receptorAC133 AntigenCells CulturedSmad4 ProteinAged 80 and overCulturedColon Cancerintegumentary systemGastroenterologyCell DifferentiationBMP4 colon stem cellsMiddle AgedCDOxaliplatinTumor Resistance to ChemotherapyBone morphogenetic protein 4Adenomatous Polyposis Coliembryonic structuresNeoplastic Stem CellsFemaleMicrosatellite InstabilityFluorouracilStem cellColorectal Neoplasmsanimal structuresCellsAntineoplastic AgentsBiologyBone morphogenetic proteinSettore MED/04 - PATOLOGIA GENERALECancer stem cellAntigens CDPTENAnimalsHumansAntigensneoplasmsPI3K/AKT/mTOR pathwayAgedGlycoproteinsNeoplasiaHepatologyPTEN Phosphohydrolasedigestive system diseasesMutationCancer researchbiology.proteinPhosphatidylinositol 3-KinasePeptidesProto-Oncogene Proteins c-aktGastroenterology
researchProduct

Inhibitory purinergic transmission in mouse caecum: Role for P2Y1 receptors as prejunctional modulators of ATP release

2007

Using conventional microelectrode recording techniques, we investigated, in the circular muscle of the mouse caecum, the neurotransmitter(s) involved in the neurally-evoked inhibitory junction potentials (IJPs) and the existence of possible prejunctional mechanisms controlling neurotransmitter release. Electrical field stimulation with single pulses elicited IJPs, consisting only of a "fast" hyperpolarization, while using train stimuli (30-50 Hz) the initial fast hyperpolarization was followed by a slower hyperpolarization. The fast and the slow component were selectively antagonized by apamin, a blocker of calcium-activated potassium channels, and N(omega)-nitro-l-arginine methyl ester (l-…

MaleP2Y receptormedicine.medical_specialtyAntineoplastic AgentsSuraminNitric OxideApaminSettore BIO/09 - FisiologiaSynaptic TransmissionEnteric Nervous SystemMembrane PotentialsMiceReceptors Purinergic P2Y1chemistry.chemical_compoundAdenosine TriphosphateInternal medicinePurinergic P2 Receptor AntagonistsmedicineAnimalsPPADSReceptorCecumMembrane potentialReceptors Purinergic P2General NeurosciencePurinergic receptorMembrane ProteinsHyperpolarization (biology)Electric StimulationReceptors Purinergic P2Y12Potassium channelMice Inbred C57BLEndocrinologyApaminchemistryBiophysicsenteric nerves intestinal muscle ATP purinergic receptors inhibitory junction potentialsNeuroscience
researchProduct

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients

2015

// Bruno Vincenzi 1 , Chiara Cremolini 2 , Andrea Sartore-Bianchi 3 , Antonio Russo 4 , Francesco Mannavola 5 , Giuseppe Perrone 6 , Francesco Pantano 1 , Fotios Loupakis 2 , Daniele Rossini 2 , Elena Ongaro 7 , Erica Bonazzina 3 , Emanuela Dell’Aquila 1 , Marco Imperatori 1 , Alice Zoccoli 1 , Giuseppe Bronte 4 , Giovanna De Maglio 7 , Gabriella Fontanini 8 , Clara Natoli 9 , Alfredo Falcone 2 , Daniele Santini 1 , Andrea Onetti-Muda 6 , Salvatore Siena 3 , Giuseppe Tonini 1 and Giuseppe Aprile 7 1 Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy 2 Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy 3 Niguarda Cancer Center, Osped…

MalePathologyColorectal cancerSettore MED/06 - Oncologia MedicaColorectal NeoplasmRetrospective StudieAntineoplastic Combined Chemotherapy ProtocolsTumor Cells Culturededucation.field_of_studyUnivariate analysisBevacizumab; Colorectal cancer; K-Ras; Mutation rate; Prognosis; OncologyLiver NeoplasmsMiddle AgedPrognosisBevacizumabSurvival RateOncologyLiver NeoplasmCohortFemaleK-Ras; mutation rate; colorectal cancer; bevacizumab; prognosisColorectal NeoplasmsK-RasResearch Papermedicine.drugHumanmedicine.medical_specialtyBevacizumabPrognosiMutation ratePopulationBevacizumab; Colorectal cancer; K-Ras; Mutation rate; Prognosis; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins p21(ras); Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Rate; Tumor Cells Cultured; OncologyReal-Time Polymerase Chain ReactionFollow-Up StudieProto-Oncogene Proteins p21(ras)Internal medicinemedicineHumanseducationSurvival rateRetrospective StudiesNeoplasm StagingAntineoplastic Combined Chemotherapy Protocolbusiness.industryCancerRetrospective cohort studymedicine.diseaseColorectal cancerK-RaMutationbusinessFollow-Up Studies
researchProduct

Differences among young adults, adults and elderly chronic myeloid leukemia patients

2014

Abstract BACKGROUND: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. PATIENTS AND METHODS: To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CML WP over a 40-year period. RESULTS: Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old)…

MalePediatricsHost responseBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Oncology; HematologyTyrosine kinase inhibitorDiseaseAntineoplastic AgentTyrosin kinase inhibitorProtein-Tyrosine Kinasehemic and lymphatic diseases80 and overAge FactorProspective StudiesYoung adultChronicBCR-ABLAged 80 and overLeukemiaIncidence (epidemiology)Chronic myeloid leukemiaAge FactorsMyeloid leukemiaHematologyMiddle AgedProtein-Tyrosine KinasesPrognosisLeukemiaOncologybcr-abl1FemaleBCR-ABL; chronic myeloid leukemia; prognosis; tyrosine kinase inhibitors; young adultsHumanAdultyoung adultsmedicine.medical_specialtyPrognosiProtein Kinase InhibitorAntineoplastic Agentschronic myeloid leukemia; bcr-abl1; Tyrosin kinase inhibitor; prognosis; young adultsNOYoung Adultchronic myeloid leukemiaLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young AdultProtein Kinase InhibitorsAgedTyrosine kinase inhibitorsAdult patientsbusiness.industrymedicine.diseaseClinical trialBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Hematology; OncologyProspective StudieBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Medicine (all); Hematology; OncologyImmunologySplenomegalyBCR-ABL PositiveBCR-ABL chronic myeloid leukemia prognosis tyrosine kinase inhibitors young adultsprognosisbusinessSpleenYoung adultsMyelogenous
researchProduct

Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity

2017

Background Continuous infusion of doxorubicin has been a strategy to reduce cardiotoxicity. Epirubicin is another anthracycline in common clinical use. However, evidence is lacking regarding whether this strategy can reduce cardiotoxicity of epirubicin without compromising antineoplastic efficacy. Design and methods Healthy rats were randomized into groups: epirubicin (8 mg/kg) delivered intraperitoneally via micro osmotic pumps (MOP), epirubicin (8 mg/kg) by intraperitoneal (IP) bolus injection, and placebo control. Blood samples were collected for analyzing biomarkers of myocardial injury and pharmacokinetics. At chosen times, sub-groups of animals were sacrificed for histopathology. A mo…

MalePhysiologyCancer Treatmentlcsh:Medicine030204 cardiovascular system & hematologyPharmacologyBiochemistryRats Sprague-DawleyMice0302 clinical medicineBolus (medicine)Intraperitoneal InjectionsBreast TumorsMedicine and Health Scienceslcsh:Scienceskin and connective tissue diseasesInfusions IntravenousRoutes of AdministrationMultidisciplinaryAntibiotics AntineoplasticArea under the curveHeartAnimal ModelsBody FluidsBloodExperimental Organism SystemsOncology030220 oncology & carcinogenesisAnatomyEpirubicinmedicine.drugResearch ArticleAnthracyclineMouse ModelsResearch and Analysis MethodsBlood Plasma03 medical and health sciencesModel OrganismsPharmacokineticsIn vivoCell Line TumorBreast CancermedicineAnimalsDoxorubicinPharmacokineticsAnimal Models of DiseaseEpirubicinPharmacologyCardiotoxicitybusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesRatsAnimal Studieslcsh:QbusinessBiomarkersPLoS ONE
researchProduct